Lannett Company, Inc. LCI today announced that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) of Phentermine HCl Capsules, 37.5 mg. Phentermine HCl Capsules, 37.5 mg, is therapeutically equivalent to the reference listed drug, Adipex-P® Capsules, 37.5 mg, of Teva Pharmaceuticals USA. Sales of Phentermine HCl Capsules, 37.5 mg, at Average Wholesale Price were approximately $8.8 million for the year ending May, 2011, according to Wolters Kluwer.
Additional sales of this drug are made through bariatric centers. The company expects to commence shipping the product shortly.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in